Funda Kosova


Breast cancer today is the most frequent cancer among women, and the second most common cause of cancer deaths among women.  The aim of this study was to synthesize a new benzoxazole derivative, scan it for anti-cancer potential by MTT test using different breast cancer cell lines, and examine its effects on NF-κB and apoptosis-related proteins (APAF-1, cytochrome C, caspase-3, bcl-2) by Real time PCR method.

Material and Method

A newly-synthesized benzoxazole-derived compound was applied to breast cancer cell lines (MDA-MB, MCF-7) and its cytotoxicity was measured quantitatively by MTT test.  Later, the level of its effects on NF-κB and apoptosis-related proteins (APAF-1, cytochrome C, caspase-3, bcl-2) were examined by Real time PCR method.


The structure of the compound synthesized in our study (5-AMINO-2-(P-BROMOFENIL-) BENZOKSAZOLÜN) was proved by elemental analysis, IR, 1H NMR and mass spectroscopy analysis methods.  When the toxic effects of the application of BTHB on the cell lines was examined by MTT, it had a greater toxic effect on MCF-7 when compared with MDA-MB, and IC50 levels were lower.  When the protein was examined in immunohistochemistry with regard to VEGF, eNOS and TUNEL, it was observed that it caused a reduction in VEGF and an increase in eNOS and TUNEL.  In the assay of the proteins by Real time PCR, when heterocyclic compounds were added to the MDA-MBA cell line, there was no difference from the control group in Nfkβ,  Caspase, Cytochrome C, but Apaf-1, BCL-2  levels are increased compared with the control group. When heterocyclic compounds were added to the MCF-7 cell line, an decrease was shown in the Nfkβ,  Caspase, Cytochrome C, Apaf-1, BCL-2 compared to the control group,


It is felt that this newly synthesized heterocyclic compound increases apoptosis by increasing the activation of Apaf-1, BCL-2, and in this way has shown an effect of inhibiting tumor growth in cancer treatment.  In addition, it is felt that this can provide hope in cancer treatment by the increased use of this drug after phase 1, phase 2 and phase 3 trials on more patient populations


Heterosiklik Bileşik, NF-κB, APAF-1, sitokrom C, kaspaz-3, bcl-2



  • There are currently no refbacks.

© Copyright 2016. All Rights Reserved - Innovatpublisher CC BY Creative commons